Invivyd, Inc. — Director's Dealing 2021

Aug 13, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Adagio Therapeutics, Inc. (ADGI)
CIK: 0001832038
Period of Report: 2021-08-10

Reporting Person: Adimab, LLC (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-08-10	Common Stock	C	25860700	—	Acquired	27845995	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-08-10	Series A Preferred Stock	$	C	5000000	Disposed		Common Stock (25000000)	Direct
2021-08-10	Series B Preferred Stock	$	C	44076	Disposed		Common Stock (220380)	Direct
2021-08-10	Series C Preferred Stock	$	C	128064	Disposed		Common Stock (640320)	Direct

Footnotes

F1: Each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock automatically converted, without payment of additional consideration, into Common Stock on a 5:1 basis immediately prior to the closing of the Issuer's initial public offering of its Common Stock and had no expiration date.